SCHEMBL26515833

SCHEMBL26515833

CNCCCCN(C)c1ccc(C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
USP2 O75604 1/20 0.39
L3MBTL4 Q8NA19 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
CNR1 P21554 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
CA12 O43570 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
SIGMAR1 Q99720 1/20 0.35
CHRM2 P08172 1/20 0.35
ALOX15 P16050 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SYK P43405 1/20 0.34
CARM1 Q86X55 1/20 0.34
PRMT1 Q99873 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16520720 0.84 ALDH1A1 (0.50) RAB9AALDH1A1TSHRUSP2CNR1
SCHEMBL6390732 0.84 ALDH1A1 (0.42) ALDH1A1TSHRMAPTL3MBTL1SIGMAR1
SCHEMBL6234580 0.82 ALDH1A1 (0.41) ALDH1A1TSHRMAPTL3MBTL1SIGMAR1
SCHEMBL12789301 0.82 ALDH1A1 (0.52) RAB9AALDH1A1TSHRUSP2CNR1
SCHEMBL13261438 0.79 MAPT (0.51) RAB9AALDH1A1TSHRMAPT
SCHEMBL6387441 0.78 ALDH1A1 (0.43) ALDH1A1TSHRMAPTL3MBTL1ALOX15
SCHEMBL14947358 0.77 MAPT (0.50) RAB9AALDH1A1TSHRMAPT
SCHEMBL28526661 0.77 MAPT (0.50) RAB9AALDH1A1TSHRMAPT
SCHEMBL1268734 0.77 L3MBTL1 (0.47) ALDH1A1TSHRUSP2CNR1MAPT
SCHEMBL14303779 0.77 ALDH1A1 (0.43) RAB9AALDH1A1TSHRUSP2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321033-A1 THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS ENYO PHARMA (FR) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321033-A1 THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS TST, TPMT, MMP1 RAB9A 2885/4885ALDH1A1 383/4885TSHR 2177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.